You Position: Home > Paper

T790M突变耐药肺癌患者靶向治疗的优化策略及研究前景

( views:145, downloads:482 )
Author:
No author available
Journal Title:
Chinese Journal of Tuberculosis and Respiratory Diseases
Issue:
10
DOI:
10.3760/cma.j.issn.1001-0939.2018.10.003
Key Word:
No keyword available

Abstract: 表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKI)已成为突变阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的一线标准治疗,无进展生存时间(progress free survival,PFS)显著优于化疗患者[1-4].但多数患者在用药1年左右会出现耐药,耐药已成为限制EGFR-TKI临床应用的瓶颈,是亟待解决的问题之一.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn